Clinical Diabetes 25:36-38, 2007
© American Diabetes Association ®, Inc., 2007
Overcoming Barriers to the Initiation of Insulin Therapy
Martha M. Funnell, MS, RN, CDE
 |
Introduction
|
|---|
New recommendations for the management of type 2 diabetes call for
more rapid initiation of both oral medications and insulin
therapy.1 Although
most providers agree that insulin is an efficacious approach to the management
of type 2 diabetes, many still consider insulin therapy as the last resort and
indicate that their patients are hesitant to take
insulin.2 In
addition, the initiation of insulin therapy is difficult in the confines of a
10-minute office visit.
 |
Assessment of Barriers
|
|---|
The first step is to determine the patient's view of insulin therapy and
correctly identify barriers from the patient's perspective. The discussion
about the need for insulin therapy affects people differently. Some may feel
angry or betrayed, others fear that insulin will add to the burden and stress
of managing diabetes, and still others may feel overwhelmed or
frightened.3
To determine a patient's concerns, ask questions such as:
- What do you need to know to consider insulin therapy?
- What problems do you think you will encounter?
- What do you see as the biggest negative of insulin? The greatest
benefit?
- What would help you overcome your concerns?
- Are you willing to try insulin? If not, what would cause you to consider
insulin?
The first response to such questions is very rarely a full accounting of
the patients' true concerns. Continuing to ask questions, such as "Why
do you think that is?" or "Can you tell me more about that?"
will help both you and the patient better understand the existing barriers so
that you can best support patients in the decision-making process.
 |
Patient-Identified Barriers to Insulin Therapy
|
|---|
The decision to initiate insulin therapy ultimately belongs to the patient
with type 2 diabetes. Common barriers among patients include beliefs that
insulin is a personal failure, that insulin is not effective, that insulin
causes complications or even death, or that insulin injections are painful, as
well as fear of hypoglycemia, loss of independence, weight gain, and cost.
There are, however, strategies providers can use to decrease patient barriers
to insulin therapy and assist patients with the decision-making
process.4
Insulin as a personal failure
A common belief among patients is that the need for insulin therapy is
indicative of a personal failure to manage their diabetes
appropriately.2
Explaining type 2 diabetes as a progressive disease of insulin resistance and
ß-cell failure from the onset will help to diminish or even prevent this
erroneous belief. Point out to patients that they have not failed but that the
other treatment options have failed them. Although many providers use insulin
as a "threat" to promote meal planning and exercise
behaviors,2 this
strategy ultimately backfires when the patient does need insulin, despite
having made recommended mealtime and physical activity changes. Instead,
describe insulin as a logical step in the continuum of treatment.
Insulin is not effective
A surprising number of patients who participated in the Diabetes Attitudes,
Wishes, and Needs study indicated that they did not believe insulin was
effective for treating
diabetes.2 Although
the reasons behind this lack of belief were not assessed, this barrier could
stem from personal experiences in which friends or family members were
prescribed insulin in doses insufficient to lower blood glucose levels, but
still resulting in side effects such as weight gain or hypoglycemia. Although
most patients think of diabetes as a "sugar" problem, pointing out
to them that diabetes is actually an insulin problem and that the insulins
used in therapy today are very similar to the insulin that the body naturally
makes may be helpful.
In addition, providers tend to base the decision to recommend insulin on
hemoglobin A1c levels, whereas patients are often more concerned
about the effects of diabetes and its treatment on their current lives.
Assessing patients' concerns and goals is necessary to frame the messages
about insulin to match their goals beyond glucose control. For example,
patients who want more flexibility in their lives or more energy for
activities they enjoy may be more amenable to insulin therapy if they are
taught how it can be used to achieve those goals.
Insulin causes complications or death
Many patients with type 2 diabetes have had experiences with diabetes
through relatives or friends. The belief that diabetes causes complications or
death often stems from these experiences. Although it is more likely that
insulin might have delayed or prevented these complications, their beliefs
about insulin in terms of its cause of and effect on these events continues.
Although it is tempting to provide information about insulin to counteract
these beliefs, facts alone often do very little to allay patients' fears. It
is generally more helpful to respond by acknowledging the patient's fears and
then providing information about the provider's experiences. For example,
"I understand your concern, but would it help to know that I have cared
for many patients with type 2 diabetes, and I have never known anyone who
became impotent as a result of insulin therapy?"
Insulin injections are painful
Many patients equate insulin injections with inoculations or injections of
antibiotics that they have experienced in the past. Point out that insulin
needles are smaller and thinner than ever before and that most patients find
it less painful than testing their blood glucose levels. Other strategies that
educators often use to overcome this barrier are to give a dry injection to
themselves in front of the patient or to ask patients to give a dry injection
to themselves at the time of the initial education, regardless of whether
insulin is indicated. Insulin pens can also be helpful for patients who are
concerned about the pain of injections. Although these patients are often
described as "needle phobic," very few patients have true needle
phobias. For those who do, psychological counseling is often needed and
effective.
Fear of hypoglycemia
The fear of hypoglycemia often stems from observing people with diabetes
who take insulin. Assessing what they have observed and the outcome of the
hypoglycemic event is needed to address the patient's specific fear. Point out
that with the use of newer rapid-acting and long-acting insulins, hypoglycemia
is less likely to occur and that very few patients with type 2 diabetes
actually have severe hypoglycemia. Reassure patients that you can teach them
strategies so that they can prevent, recognize, and treat hypoglycemia and
thus avoid severe events.
Change in lifestyle
A concern among older adults or patients who live alone is that once they
begin insulin therapy, it will adversely affect their independence, either
because of hypoglycemia or because they fear they will not be able to draw up
or administer their own injections. Providing information about insulin pens
or other devices to increase accuracy and ease of administration and about
local home-care resources may help to diminish these barriers. Teaching
patients to correctly identify symptoms of hypoglycemia and strategies to
facilitate insulin use is also often helpful.
Other lifestyle concerns are related to timing, difficulty in traveling,
and loss of spontaneity and flexibility. If patients identify these concerns,
provide information about insulin regimens that offer maximum flexibility,
strategies for traveling with insulin, or other identified lifestyle
barriers.
Some of these barriers result from concerns about injecting insulin away
from home, for example in public places or at work. Some patients worry that
if they inject in public places they will be perceived as injecting illegal
drugs. Insulin pens can be very helpful for overcoming this barrier by
increasing patients' ability to inject discretely. Using only morning and/or
bedtime insulin regimens can also eliminate this barrier for some
patients.
Some patients have justifiable concerns about the loss of their jobs if
they need to begin insulin therapy. Although there are some occupations for
which this is true, the Americans With Disabilities Act requires employers to
make reasonable accommodations for patients with diabetes, including those who
take insulin. In addition, the regimen may be adjusted to allow for insulin
injections to be given while patients are at home instead of at work.
Insulin causes weight gain
It is true that many patients who begin insulin therapy gain weight with
improved glycemia and greater meal plan flexibility. If this is a barrier,
offer to arrange a meeting with a dietitian before the initiation of insulin
to identify strategies to prevent weight gain.
Insulin is too expensive
There is no question that diabetes is expensive, particularly for patients
who have limited drug coverage or no insurance at all. Generally, however,
insulin is less expensive than using multiple oral medications to produce the
same glycemic outcomes. The regimen may also be adjusted to decrease this
barrier by using premixed insulins if co-pays are a concern or less expensive
insulins for patients with no or limited drug coverage. Other strategies to
reduce this barrier include teaching patients to reuse insulin syringes,
adjusting the monitoring schedule to reduce the cost of strips and other
supplies, providing information about the least expensive sources for insulin
and other supplies in your area, prescribing less expensive insulins, and
referring patients to pharmaceutical company assistance programs. Because
prices can vary a great deal at different pharmacies, provide a list of prices
for pharmacies in your area or suggest to patients that they shop around for
the best prices. This is also a good opportunity to review all medications to
determine if any could be eliminated, decreased, or provided in combination
form to lower out-of-pocket expenditures.
 |
Provider-Identified Barriers to Insulin Therapy
|
|---|
Although patient-identified barriers are the most common reasons cited for
delay in initiating insulin therapy, many providers also are hesitant to
initiate insulin. Because provider attitudes are crucial for patient
acceptance of insulin, it is important to determine whether "clinician
inertia" is affecting your practice. Along with overcoming patient
barriers, there are also strategies providers can use to overcome their own
barriers to insulin therapy.
Refer patients for diabetes self-management education and medical nutrition therapy
Diabetes educators can be powerful allies in helping patients make the
decision to initiate insulin therapy and assisting with insulin dose
titration. Recent changes in Medicare, Medicaid, and other insurance packages
have greatly increased the likelihood of reimbursement for these essential
services.
Provide ongoing self-management support
Patients need not only initial education about insulin but also continued
followup and support to sustain gains in diabetes self-care behaviors. Office
staff can be extremely helpful in supporting and reinforcing patients'
self-management efforts related to insulin therapy, particularly in the early
phases, when doses are being titrated frequently.
Adopt successful strategies
Consider implementing strategies used by other successful practices, such
as creating collaborative relationships with patients and designing systems to
facilitate chronic disease care. Create proactive methods to evaluate outcomes
and monitor results so that the time spent with patients can be used most
efficiently and effectively. Establishing a plan with patients for follow up
of blood glucose results by telephone or in person will also facilitate the
appropriate titration of insulin and its effectiveness.
Address emotional issues
Although it is important to address concerns about diabetes in general,
when discussing the initiation of insulin therapy, it is essential to ask
patients about their thoughts or feelings about insulin. This is the most
efficient way to ensure that the messages about insulin are supportive,
tailored for each individual patient, and effective.
 |
Footnotes
|
|---|
Martha M. Funnell, MS, RN, CDE, is co-director of the Behavioral,
Clinical, and Health Systems Intervention Research Core at the Diabetes
Research and Training Center of the University of Michigan in Ann Arbor. She
is an associate editor of Clinical Diabetes.
Note of disclosure: Ms. Funnell has served on advisory panels
and received honoraria or consulting fees from Novo Nordisk, Eli Lilly and
Co., and Sanofi-Aventis. These companies manufacture insulin products for the
treatment of diabetes.
 |
REFERENCES
|
|---|
1 Nathan DM, Buse
JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of
hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and
adjustment of therapy. Diabetes Care29
: 1963-1972,2006[Free Full Text]2 Peyrot M, Rubin
RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil
L, the International DAWN Advisory Panel: Resistance to insulin therapy among
patients and provides: results of the cross-national Diabetes Attitudes,
Wishes and Needs study. Diabetes Care28
: 2673-2679,2005[Abstract/Free Full Text] 3 Funnell MM, Kruger
DF: Type 2 diabetes: treat to target. Nurse Pract29
: 11-23,2004[Medline] 4 Funnell MM, Kruger
DF: Self-management support for insulin therapy in type 2 diabetes.
Diabetes Educ 30:274
-280, 2004[Free Full Text]

CiteULike Del.icio.us Digg Reddit Technorati What's this?
|
|
|